E A D R

Pharmacology in Critical Care
E
FFECT OF
ALBUMIN ON
DIURETIC RESPONSE TO
FUROSEMIDE IN PATIENTS
WITH HYPOALBUMINEMIA
By Thitima Doungngern, PharmD, BCPS, Yvonne Huckleberry, PharmD, BCPS,
John W. Bloom, MD, and Brian Erstad, PharmD.
C N E 1.0 Hour
Notice to CNE enrollees:
A closed-book, multiple-choice examination
following this article tests your understanding of
the following objectives:
1. Examine the effect of albumin on the diuretic
effect of furosemide.
2. Correlate findings of various studies related to
the sequential administration of albumin and
furosemide.
3. Identify study limitations and opportunities
for future research related to administration of
furosemide and albumin.
To read this article and take the test online,
visit www.ajcconline.org and click “CNE Articles in This Issue.” No fee for AACN members.
©2012 American Association of Critical-Care Nurses
doi: http://dx.doi.org/10.4037/ajcc2012999
280
Background Albumin is broadly prescribed for critically ill
patients although it does not have a mortality benefit over
crystalloids. One common use of albumin is to promote diuresis.
Objectives To compare urine output in patients treated with
furosemide with and without albumin and to assess other
variables possibly associated with enhanced diuresis.
Methods A retrospective study was conducted on patients in
a medical intensive care unit who received furosemide therapy
as a continuous infusion with and without 25% albumin for
more than 6 hours. Primary end points were urine output and
net fluid loss.
Results A total of 31 patients were included in the final analysis.
Mean urine output in patients treated with furosemide alone did
not differ significantly from output in patients treated with furosemide plus albumin at 6, 24, and 48 hours: mean output, 1119
(SD, 597) mL vs 1201 (SD, 612) mL, P = .56; 4323 (SD, 1717) mL
vs 4615 (SD, 1741) mL, P = .42; and 7563 mL (SD, 2766) vs 7432
(SD, 2324) mL, P = .94, respectively. Additionally, net fluid loss
did not differ significantly between the 2 groups at 6, 24, and
48 hours. Higher concentrations of serum albumin did not
improve urine output. The only independent variable significantly associated with enhanced urine output at 24 and 48
hours was increased fluid intake.
Conclusion Addition of albumin to a furosemide infusion did
not enhance diuresis obtained with furosemide alone in critically ill patients. (American Journal of Critical Care. 2012;21:
280-286)
AJCC AMERICAN JOURNAL OF CRITICAL CARE, July 2012, Volume 21, No. 4
www.ajcconline.org
V
olume overload, a common problem in critically ill patients, is typically treated with
fluid restriction and diuretics. Furosemide is the loop diuretic most often prescribed
to enhance urine output in these patients. Compared with bolus administration,
continuous infusion of furosemide may improve diuresis with fewer adverse effects.1,2
However, furosemide resistance may occur in critically ill patients despite alterations
in dosing regimens, making it difficult to achieve goals for fluid output.2
The mechanism of diuretic resistance remains
unclear, but hypoalbuminemia may be one of the
causes.2 A preliminary study by Inoue et al3 indicated
that the combination of furosemide and albumin,
given as a single bolus, was as effective as the same
dose of furosemide alone in improving urine output
in patients with diuretic resistance. Maximal urine
output occurred within 1 hour in both groups of
patients. Patients had various diagnoses, and the
clinical design of the study3 is not well described.
In subsequent studies4-8 with improved designs, the
effects of furosemide plus albumin in specific populations of patients such as those with nephrotic syndrome and cirrhosis with ascites were conflicting.
Most recently, Martin et al9 suggested that furosemide
plus albumin may be better than furosemide alone
for the treatment of adult respiratory distress syndrome. Because of the large number of patients
needed to show potential mortality differences with
the use of albumin, investigators have focused on
more specific benefits of albumin related to oxygenation or diuresis.
Because of periodic shortages, high cost, and
potential adverse effects of albumin, studies of the
effectiveness of albumin in enhancing diuresis in
critically ill patients are needed.10 Our study was
designed to determine if continuous infusions of
25% albumin enhanced urine output when given
with continuous infusions of furosemide. We had
About the Authors
Thitima Doungngern is a member of the faculty of pharmaceutical sciences at Prince of Songkla University,
Hat Yai, Songkhla, Thailand. At the time of the study,
Doungngern was a specialized resident in internal medicine. Yvonne Huckleberry is a critical care pharmacist,
University of Arizona Medical Center, John W. Bloom is
an associate professor, Departments of Pharmacology
and Medicine, College of Medicine, and Brian Erstad is
a professor, College of Pharmacy, at the University of
Arizona, Tucson, Arizona.
Corresponding author: Brian Erstad, PharmD, Professor,
College of Pharmacy, University of Arizona, 1703
E Mabel St, Tucson, Arizona, 85721 (e-mail: erstad@
pharmacy.arizona.edu).
www.ajcconline.org
a unique opportunity to study this issue because
cotherapy with albumin and furosemide infusions
that may precede or follow furosemide infusions
alone are often used in the medical intensive care
unit (ICU) at Arizona Health Sciences Center, Tucson, Arizona. The primary objective of the study was
to compare urine output in patients given furosemide
alone with output in patients given both furosemide
and albumin. The secondary objective was to identify other variables that might be associated with
enhanced diuresis.
Methods
Study Design
Adult patients in the medical ICU who received
a continuous furosemide infusion with and without
25% albumin were studied retrospectively. The study was conducted
at Arizona Health Sciences Center, a
tertiary care, academic medical center. The local institutional review
board reviewed and approved the
study. Primary end points were
urine output and net fluid loss.
The diuretic effect of a continuous infusion of furosemide peaks
approximately 3 hours after the
infusion is started.3 Therefore,
cumulative urine output at 6 hours
was chosen as the initial and primary end point to
ensure measurement of the full diuretic effect of the
furosemide infusion.
Compared with
bolus, continuous
infusion of
furosemide may
improve diuresis
with fewer
adverse effects.
Selection of Patients
Any adult patient admitted to the medical ICU
between January 1, 2007, and August 31, 2010, who
received a sequential continuous furosemide infusion
for at least 6 hours and a combined furosemide
plus 25% albumin infusion for at least 6 hours was
included in the study. The order of infusion did not
matter so long as no gap occurred between the 2
sequential infusions. Patients were excluded if they
did not have sequential infusions of furosemide
AJCC AMERICAN JOURNAL OF CRITICAL CARE, July 2012, Volume 21, No. 4
281
Table 1
Baseline characteristics (N = 31)
Characteristic
Mean (SD)
Range
Age, y
54.3 (17.8)
21-84
Weight at admission, kg
78.2 (24.3)
46.5-142
Height, cm
167.2 (10.1)
148-188
0.8 (0.3)
0.5-1.5
2.1 (0.5)
1.3-3.2
Serum creatinine,
Serum albumin,
APACHE II
mg/dLa
g/dLa
scorea
SOFA scorea
Ratio of PaO2 to fraction of
inspired oxygena
20.6 (5)
13-31
7.6 (2.5)
2-12
174 (103.9)
80-465
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; SOFA,
Sequential Organ Failure Assessment.
a Day 0, the day that continuous furosemide infusion alone was started. To convert
creatinine level to micromoles per liter, multiply by 88.4.
and furosemide plus albumin, received furosemide
or furosemide plus albumin before the sequential
infusions, had incomplete intake and output records,
or had renal dysfunction (defined as serum creatinine
level greater than 1.5 mg/dL; to convert to micromoles
per liter, multiply by 88.4), or any current renal disease (eg, acute tubular necrosis, glomerulonephritis).
Data Collection
Baseline data collected included age, sex, height,
weight, serum level of creatinine, serum level of
albumin, diuretic medications, ICU diagnosis and
underlying illnesses, ratio of PaO2 to fraction of
inspired oxygen, and scores on the Acute Physiology and Chronic Health Evaluation II and the
Sequential Organ Failure Assessment. In addition,
daily measurements of serum levels
of albumin, furosemide and albumin
dosing, fluid intake, and urine output
at the first 6 hours (0-6 hours), and
every 6 hours up to 48 hours (if data
were available) in each group were
recorded.
At 48 hours,
those receiving
furosemide/albumin received more
furosemide than
those who received
furosemide alone.
Statistics
On the basis of data on urine
output in critically ill medical patients,
it was estimated that 22 patients
would be needed to detect a 30%
difference in urine output between the furosemidealone and the albumin-plus-furosemide groups with
80% power and α = .05. However, it was decided to
enroll at least 30 patients to decrease the risk of a
type II error.
Continuous data for comparison of the 2 groups
of patients were evaluated by using paired t tests or
repeated-measures analysis of variance. A 2-sample
282
t test was used to evaluate unpaired data. Linear
regression analysis was used to investigate relationships between the dependent variable urine output
and demographic independent variables (age, weight,
severity of illness) and other independent variables
(ie, furosemide or albumin dose, fluid intake, and
serum albumin concentrations) at 24 and 48 hours
for both groups of patients. Significance was defined
as P < .05 unless otherwise noted (Bonferroni correction for post hoc testing). All data are reported
as mean and standard deviation.
Results
A total of 170 patients received continuous
infusions of furosemide and 25% albumin during
the study period. Thirty-six of these patients met the
inclusion criteria of receiving continuous infusions
of furosemide with and without 25% albumin for
at least 6 hours. Of these, 5 patients had serum creatinine levels greater than 1.5 mg/dL and/or acute
tubular necrosis. Therefore, data on 31 patients were
included in the final analysis. Of the 31 patients, 17
initially received furosemide infusions; the other 14
patients initially received infusions of furosemide
plus albumin.
A total of 19 patients (61%) were women, and
the mean age was 54.3 years. The 3 most common
underlying illnesses were cancer (36%), most often
skin cancer; cardiovascular disease (23%); and liver
disease (16%), mostly due to hepatitis C. A total of
26 patients (84%) had a ratio of PaO2 to fraction of
inspired air less than 300. Other baseline characteristics are presented in Table 1.
Table 2 shows data for the patients who received
furosemide alone and furosemide plus albumin.
The infusion rate for furosemide was initiated at 2
to 5 mg/h and titrated in an attempt to achieve a
urine output 50 to 100 mL/h greater than fluid
intake. The infusion rate for 25% albumin was 8 or
10 mL/h in all but 3 patients (rates of 5 mL/h for 2
patients and 12 mL/h for 1 patient). The median
initial furosemide dose was 4 mg/h in patients who
received furosemide alone and 5 mg/h in patients
who received furosemide plus albumin. Differences
in furosemide dose between the 2 groups at 6 hours
(P = .33) and 24 hours (P = .50) were not significant.
At 48 hours, the patients who received furosemide
plus albumin received more furosemide than did the
patients who received furosemide alone (P = .04).
Urine output did not differ significantly between
the 2 groups at 6, 24, or 48 hours (P values: .56, .42,
and .94, respectively). Similarly, urine output did
not differ significantly within the furosemide-alone
group (P = .09) and the furosemide-plus-albumin
AJCC AMERICAN JOURNAL OF CRITICAL CARE, July 2012, Volume 21, No. 4
www.ajcconline.org
Table 2
Continuous data for the furosemide and
combined albumin plus furosemide groupsa
Furosemide alone
Time, h
Furosemide
Fluid
dose, mg
intake, mL
0-6 (N = 31)
43 (42)
0-24 (n = 15) 148 (120)
0-48 (n = 5)
a
b
265 (246)a
Furosemide plus albumin
Urine
output, mL
Net fluid
loss, mL
Furosemide
dose, mg
52 (43)
Albumin
dose, mL
Fluid
intake, mL
Urine
output, mL
Net fluid
loss, mL
56.6 (8.5)
905 (383)
1201 (612)
-295 (571)
937 (441)
1119 (597)
-181 (646)
3136 (1114)
4323 (1717)
-1187 (1594)
165 (77)
237 (22)
3694 (1459)
4615 (1741)
-921 (1194)
6072 (2814)
7563 (2766)
-1491 (2711)
420 (231)b
442 (53)
6276 (2635)
7432 (2324)
-1156 (3299)
All values are mean (SD).
P = .04 for the furosemide dose at 48 hours; all other comparisons were not significantly different.
group (P = .89) according to the order in which the
infusions were administered as the primary end
point. Additionally, net fluid loss did not differ significantly between the 2 groups at 6, 24, or 48
hours (P values: .42, .47, and .82, respectively).
Table 3 shows the relationship between urine
output and independent variables according to simple regression analysis. Fluid intake was the only
significant predictor of increased urine output for
both the furosemide-alone group (P = .02; R2 = 0.27)
and the furosemide-plus-albumin group (P = .004;
R2 = 0.29) at 24 and 48 hours. In the patients given
furosemide plus albumin, serum levels of albumin
increased from 6 to 24 hours (mean, 2.0 g/dL [SD,
0.46] to 2.4 g/dL [SD, 0.47]; P = .04) and from 24 to
48 hours (mean, 2.4 g/dL [SD, 0.47] to 2.8 g/dL
[SD, 0.45] P = .02), but only the 6 to 48 hour increase
(mean, 2.0 g/dL [SD, 0.46] to 2.8 g/dL [SD, 0.45];
P < .001) was significant with post hoc adjustment
of P values.
Discussion
This study is the first one done to determine
whether or not continuous infusion of 25% albumin
enhances furosemide-induced diuresis in critically
ill patients. We found that the effect of coadministration of furosemide and albumin was no greater
than that of continuous infusion of furosemide alone.
Various beneficial mechanisms of the action of
albumin beyond simple volume expansion have been
described. For example, an early evaluation3 of furosemide mixed with an equimolar solution of albumin in analbuminemic rats suggested that albumin
might play an important role in delivering furosemide to its site of action in the kidneys, thereby
enhancing diuresis. In contrast, in a study4 in rats
with nephrotic syndrome, the response to furosemide
was compromised when the drug was given with
albumin, suggesting that furosemide binding to
albumin reduced the availability of the active compound. When medications were added that displaced
furosemide from its albumin binding site, an
www.ajcconline.org
Table 3
Simple regression analysis of independent
variables with urine output at 24 or 48 hours
Variable
P (R2 if significant)
Age (24 hours)
.14
Weight in kilograms (24 hours)
.22
APACHE II score (24 hours)
.44
SOFA score (24 hours)
.94
Furosemide dose in furosemide-alone group (24 hours)
.77
Furosemide dose in furosemide-alone group (48 hours)
.047 (0.37)
Furosemide dose in combined albumin group (24 hours)
.35
Furosemide dose in combined albumin group (48 hours)
.23
Albumin dose in combined albumin group (24 hours)
.36
Albumin dose in combined albumin group (48 hours)
.48
Albumin concentration in albumin group (24 hours)
.90
Albumin concentration in albumin group (48 hours)
.047 (0.34)
Fluid intake in furosemide-alone group (24 hours)
.02 (0.27)
Fluid intake in furosemide-alone group (48 hours)
.02 (0.45)
Fluid intake in combined albumin group (24 hours)
.004 (0.29)
Fluid intake in combined albumin group (48 hours)
.03 (0.37)
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; SOFA,
Sequential Organ Failure Assessment.
improved diuretic response occurred. These conclusions suggest that the relationship between albumin
and furosemide is not well understood.
The method of administration may influence
the efficacy of albumin for diuresis. For example,
results in normal and analbuminemic rats suggest
that albumin and furosemide administered together
form a complex that carries the furosemide to the
kidney for uptake by renal tubular cells. Our study
is the first to investigate the diuretic effects of a continuous infusion of albumin in medical ICU patients.
In previous studies focused on specific populations
of patients to whom albumin was administered via
AJCC AMERICAN JOURNAL OF CRITICAL CARE, July 2012, Volume 21, No. 4
283
intermittent boluses or short-term infusions, the
results were conflicting. In a trial of 8 patients with
nephrotic syndrome, Akcicek et al5 administered
furosemide as a 60-mg intravenous bolus followed
by a 4-hour intravenous infusion of furosemide
with and without 20% albumin. Maximal diuretic
and natriuretic responses occurred
during the drug infusions for all
groups. The addition of albumin had
no diuretic benefit. In contrast, Fliser
et al6 conducted a randomized, double-blind, placebo, controlled trial in
9 patients with nephrotic syndrome.
Patients received a 60-mg furosemide
bolus plus placebo, a 60-mg furosemide bolus plus 200 mL of 20%
albumin, or placebo given as a bolus plus 200 mL
of 20% albumin. The increase in urine output
between the 3 groups during the 8-hour monitoring
period were significant. Fliser et al noted that the
same result could possibly be achieved by optimizing the dose of furosemide alone rather than by
adding albumin.
The combination of furosemide plus albumin
for the management of ascites in patients with cirrhosis has also had conflicting results. Gentilini et
al7 performed a randomized, controlled trial of 126
patients with cirrhosis and ascites. Patients were
randomized to receive escalating doses of diuretics
with or without 25% albumin. End points of the
inpatient phase of the trial included disappearance
of ascites and duration of hospital stay. The benefits
of furosemide plus albumin were significantly better than the benefits of furosemide alone for both
end points. In contrast to these findings, Chalasani
et al8 found a lack of benefit with
furosemide plus albumin. They performed a randomized crossover
study in 13 patients with cirrhosis
and ascites to evaluate the effects of
albumin on the response to furosemide
as indicated by urinary excretion of
sodium and urine volume. Patients
received each of the following intravenously over 30 minutes: 40 mg of
furosemide alone, 25 g of albumin
alone, 40 mg of furosemide mixed
with 25 g of albumin, and 40 mg of
furosemide and 25 g of albumin infused simultaneously in different arms. Urine output for furosemide
alone was similar to that for either combination.
The diuretic and natriuretic responses returned to
normal within 6 hours of drug administration in all
arms of the study. Chalasani et al8 concluded that
The method of
administration
may influence the
efficacy of albumin for diuresis.
The one consistent factor significantly related to
increased urine
output was
increased fluid
intake.
284
coadministration of furosemide and albumin does
not improve diuresis in patients with cirrhosis with
ascites and most likely does not enhance diuresis in
other populations of patients.
Martin et al9 studied furosemide plus albumin
in patients with hypoproteinemia and acute lung
injury treated with mechanical ventilation. In this
randomized, double-blind, placebo-controlled,
multicentered trial, change in oxygenation over 24
hours was the primary end point. Net fluid loss was
a secondary outcome. A total of 40 patients received
furosemide with either a placebo or albumin. The
control group received a furosemide bolus of 20 mg
followed by a titrated infusion of up to 10 mg/h of
furosemide for 72 hours with a normal saline
placebo substituted for an equivalent volume of
albumin. The treatment group received 25 g of 25%
albumin immediately before the furosemide bolus
and every 8 hours thereafter for the same duration.
The improvement in oxygenation and net negative
fluid balance in patients who received furosemide
plus albumin was significantly greater than the
changes in patients given furosemide plus placebo.
These data are the most compelling to date that
suggest albumin may enhance the effectiveness of
furosemide in a specific population of patients.
Although a large percentage of our patients had
a ratio of PaO2 to fraction of inspired oxygen less
than 300, we did not observe a beneficial diuretic
effect with the addition of albumin. One difference
in design between our study and that of Martin et
al9 is that we used continuous infusions of albumin
rather than boluses. Also, we cannot exclude a relationship between increasing albumin concentrations
and increased diuretic response. This possibility
might account for the net fluid loss noted at 72
hours in the study by Martin et al.
In our regression analysis, albumin concentration at 48 hours was associated with urine output,
but this finding was based on data from only 5
patients. Furthermore, by 48 hours, significantly
more furosemide had been administered to patients
receiving furosemide plus albumin than to patients
given furosemide alone, a situation that could also
explain the increased urine output at this time. In
our study, the one consistent factor significantly
related to increased urine output was increased
fluid intake.
Although hyperoncotic albumin may have
potential benefits in specific populations of
patients, we conclude that the addition of a 25%
albumin infusion to continuous infusion with
furosemide does not improve diuresis in critically
ill patients with hypoalbuminemia. In agreement
AJCC AMERICAN JOURNAL OF CRITICAL CARE, July 2012, Volume 21, No. 4
www.ajcconline.org
with previous studies, we recommend optimizing
the furosemide dosing before considering the addition of colloid. Furthermore, if diuretic resistance
occurs, the addition of a thiazide diuretic may produce a better result and be more cost-effective in
achieving diuresis in patients with volume overload
whose hemodynamic status is stable.2
Our study had some limitations. Because the
study was retrospective, incorrectly recorded information and uncontrolled confounders are possible.
For example, details of patients’ characteristics that
might have influenced the response to furosemide
or the combination regimen may have been missed.
Because of limited enrollment, we did not perform
subgroup analyses to evaluate whether albumin is
beneficial in specific populations of patients in the
ICU. Furthermore, the limited number of patients at
the final 48-hour end point prohibits firm conclusions about an effect or lack of effect of albumin in
enhancing furosemide diuresis with more prolonged
administration. Finally, we evaluated the use of continuous infusions of albumin and furosemide at
only a single institution, so our results may not be
generalizable to other ICUs.
Conclusions
Compared with continuous infusion of
furosemide alone, administration of furosemide
plus albumin given as a continuous infusion did
not improve urine output in critically ill patients.
Furthermore, cumulative fluid loss did not differ
between the 2 groups. Enhanced urine output was
associated solely with increased fluid intake and not
with other independent variables such as serum
levels of albumin.
ACKNOWLEDGMENTS
This work was performed at the Arizona Health Sciences
Center in Tucson, Arizona.
www.ajcconline.org
FINANCIAL DISCLOSURES
None reported.
eLetters
Now that you’ve read the article, create or contribute to an
online discussion on this topic. Visit www.ajcconline.org
and click “Submit a response” in either the full-text or
PDF view of the article.
REFERENCES
1. Sanjay S, Annigeri RA, Seshadri R, Rao BS, Prakash KC,
Mani MK. The comparison of the diuretic and natriuretic
effect of continuous and bolus intravenous furosemide in
patients with chronic kidney disease. Nephrology (Carlton).
2008;13(3):247-250.
2. Asare K. Management of loop diuretic resistance in the intensive care unit. Am J Health Syst Pharm. 2009;66:1635-1640.
3. Inoue M, Okajima K, Itoh K, et al. Mechanism of
furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int. 1987;32(2):198-203.
4. Kirchner KA, Voelker JR, Brater DC. Binding inhibitors
restore furosemide potency in tubule fluid containing albumin. Kidney Int. 1991;40:418-424.
5. Akcicek F, Yalniz T, Basci A, Ok E, Mees EJ. Diuretic effect
of furosemide in patients with nephrotic syndrome: is it
potentiated by intravenous albumin? BMJ. 1995;310(6973):
162-163.
6. Fliser D, Zurbruggen I, Mutschler E, et al. Coadministration
of albumin and furosemide in patients with the nephrotic
syndrome. Kidney Int. 1999;55(2):629-634.
7. Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin
improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J
Hepatol. 1999;30(4):639-645.
8. Chalasani N, Gorski JC, Horlander JC, et al. Effects of albumin/furosemide mixtures on responses to furosemide in
hypoalbuminemic patients. J Am Soc Nephrol. 2001;12(5):
1010-1016.
9. Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA,
Bernard GR. A randomized, controlled trial of furosemide
with or without albumin in hypoproteinemic patients with
acute lung injury. Crit Care Med. 2005;33(8):1681-1687.
10. Dorhout Mees EJ. Does it make sense to administer albumin to the patient with nephrotic oedema? Nephrol Dial
Transplant. 1996;11(7):1224-1226.
To purchase electronic or print reprints, contact The
InnoVision Group, 101 Columbia, Aliso Viejo, CA 92656.
Phone, (800) 899-1712 or (949) 362-2050 (ext 532); fax,
(949) 362-2049; e-mail, [email protected].
AJCC AMERICAN JOURNAL OF CRITICAL CARE, July 2012, Volume 21, No. 4
285
CNE Test
Test ID A1221043: Effect of Albumin on Diuretic Response to Furosemide in Patients With Hypoalbuminemia.
Learning objectives: 1. Examine the effect of albumin on the diuretic effect of furosemide. 2. Correlate findings of various studies related to the sequential administration of albumin and furosemide. 3. Identify study limitations and opportunities for future research related to administration of furosemide and albumin.
1. Which of the following is the most frequently used treatment for
volume overload in critically ill patients?
a. Thiazide diuretics and fluid restriction
b. Fluid restriction and albumin
c. Fluid restriction and loop diuretics
d. Albumin and thiazide diuretics
6. How many patients would be needed to detect a 30% difference in urine
output between furosemide alone and the albumin plus furosemide
group?
a. 53
b. 67
c. 170
d. 22
2. Which of the following is the primary objective of this study?
a. To compare urinary output in patients given furosemide and albumin injections
every 6 hours
b. To compare urinary output in patients given furosemide alone with output in
patients given both furosemide and albumin
c. To compare urinary output in patients given furosemide alone with output in
patients given furosemide and thiazide diuretic
d. To compare urinary output in patients given furosemide alone with output in
patients given furosemide and thiazide diuretics
3. Which of the following statements best describes the study design?
a. Adult patients in a medical intensive care unit (ICU) receiving a continuous
furosemide infusion with and without 25% albumin; diuretic effect measured
at 30-minute increments
b. All adult ICU patients receiving a continuous thiazide infusion with and
without 25% albumin; diuretic effect measured at 3 hours and 6 hours
c. Adult patients in an MICU receiving a continuous furosemide infusion with and
without 25% albumin; diuretic effect measured at 6 hours for primary endpoint
d. All adult patients in an MICU receiving a continuous furosemide infusion
with and without 25% albumin; diuretic effect measured at 30-minute increments
4. Which patients were excluded from the study?
a. Those who did not have sequential infusions of albumin and furosemide;
renal dysfunction, hypokalemia
b. Those who had sequential infusions of albumin and furosemide; incomplete
intake and output records, serum creatinine 1.0
c. Those who did not have sequential infusions of albumin and furosemide;
renal dysfunction, current renal disease
d. Those who had sequential infusions of albumin and furosemide; renal
dysfunction, current renal disease
7. How many patients were in the f inal study?
a. 170
b. 31
c. 36
d. 14
8. What were the 3 most common underlying illnesses seen in the patients
in this study?
a. Skin cancer, respiratory disease, cardiovascular disease
b. Skin cancer, pancreatitis, hepatitis C
c. Skin cancer, liver disease, respiratory disease
d. Skin cancer, cardiovascular disease, liver disease
9. Which of the following was the only signif icant predictor of increased
urinary output for both the furosemide and the furosemide plus albumin
group at 24 and 48 hours?
a. Fluid intake
b. Rate of furosemide infusion
c. Rate of albumin infusion
d. Time interval between furosemide and albumin infusion
10. Which of the following statements best describes the effect of
coadministration of furosemide and albumin?
a. Effect was greater than the continuous infusion of furosemide alone
b. Effect was the same for furosemide infusion alone and furosemide and albumin
administration
c. Effect was no greater than the continuous infusion of furosemide alone
d. Effect was significantly greater than the continuous infusion of furosemide alone
11. Which of the following is the recommended treatment if loop diuretic
resistance continues?
a. Add 20% albumin
b. Add loop diuretic
c. Add fluid
d. Add thiazide diuretic
5. Which of the following baseline data points were collected on
all patients?
a. Age, sex, height, weight, serum creatinine, diuretic medications, ICU diagnosis
b. Age, sex, height, weight, urine creatinine, diuretic medications, ICU diagnosis
c. Age, sex, height, weight, serum creatinine, cardiac medications, ICU diagnosis
d. Age, sex, height, weight, urine creatinine, cardiac medications, ICU diagnosis
Test ID: A1221043 Contact hours: 1.0 Form expires: July 1, 2014. Test Answers: Mark only one box for your answer to each question. You may photocopy this form.
1. ❑ a
❑b
❑c
❑d
2. ❑ a
❑b
❑c
❑d
3. ❑ a
❑b
❑c
❑d
4. ❑ a
❑b
❑c
❑d
5. ❑ a
❑b
❑c
❑d
6. ❑ a
❑b
❑c
❑d
8. ❑ a
❑b
❑c
❑d
7. ❑ a
❑b
❑c
❑d
10. ❑ a
❑b
❑c
❑d
9. ❑ a
❑b
❑c
❑d
11. ❑ a
❑b
❑c
❑d
Fee: AACN members, $0; nonmembers, $10 Passing score: 8 correct (73%) Category: Synergy CERP A Test writer: Diane Byrum
Program evaluation
Yes
❑
❑
❑
For faster processing, take
this CNE test online at
www.ajcconline.org (“CNE
Articles in This Issue”) or
mail this entire page to:
AACN, 101 Columbia,
Aliso Viejo, CA 92656.
Objective 1 was met
Objective 2 was met
Objective 3 was met
Content was relevant to my
nursing practice
❑
My expectations were met
❑
This method of CE is effective
for this content
❑
The level of difficulty of this test was:
❑ easy ❑ medium ❑ difficult
To complete this program,
it took me
hours/minutes.
No
❑
❑
❑
❑
❑
❑
Name
Address
City
Country
State
Phone
ZIP
E-mail address
AACN Customer ID#
Payment by:
Card #
❑ Visa
❑ M/C
❑ AMEX
❑ Check
Expiration Date
Signature
The American Association of Critical-Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
AACN has been approved as a provider of continuing education in nursing by the State Boards of Nursing of Alabama (#ABNP0062), California (#01036), and Louisiana (#ABN12). AACN
programming meets the standards for most other states requiring mandatory continuing education credit for relicensure.